Provided by Tiger Trade Technology Pte. Ltd.

Ionis Pharmaceuticals

59.88
-0.4800-0.80%
Post-market: 59.880.00000.00%19:30 EDT
Volume:1.87M
Turnover:112.59M
Market Cap:9.95B
PE:-17.21
High:60.99
Open:60.37
Low:59.78
Close:60.36
52wk High:86.74
52wk Low:49.13
Shares:166.18M
Float Shares:161.92M
Volume Ratio:0.93
T/O Rate:1.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4800
EPS(LYR):-2.3812
ROE:-105.50%
ROA:-12.42%
PB:22.63
PE(LYR):-25.15

Loading ...

Trump Administration Announces Drug Pricing Deals with CSL, Astellas and Others

Reuters
·
Yesterday

Ionis Pharmaceuticals Price Target Maintained with a $115.00/Share by HC Wainwright & Co.

Dow Jones
·
Aug 31

Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY) and Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Aug 31

Jefferies sees neutral to negative read-through to Alnylam from AstraZeneca data

TIPRANKS
·
Aug 28

Alnylam, Ionis Fall as Heart-Drug Data Raise Doubts over Combination Treatment

Reuters
·
Aug 28

Ionis Pharmaceuticals, Inc. : Bmo Initiates Coverage with Market Perform Rating; Price Target $60

THOMSON REUTERS
·
Aug 19

BMO Capital starts Ionis at Market Perform pending better visibility

TIPRANKS
·
Aug 19

Analysts Conflicted on These Healthcare Names: Definium Therapeutics (DFTX), Ionis Pharmaceuticals (IONS) and Sutro Biopharma (STRO)

TIPRANKS
·
Aug 15

Ionis Pharmaceuticals (IONS) Receives a Buy from Wells Fargo

TIPRANKS
·
Aug 14

Ionis Pharmaceuticals Earnings Call Highlights Pipeline And Growth

TIPRANKS
·
Aug 12

J.P. Morgan Reaffirms Their Buy Rating on Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Aug 10

Novartis Might Struggle to Clear Bar in Cholesterol Drug Trial

Dow Jones
·
Aug 10

Ionis Pharmaceuticals (IONS) Receives a Hold from Stifel Nicolaus

TIPRANKS
·
Aug 03

Ionis Director Michael R. Hayden Reports Acquisition of 20,000 Common Shares Worth $1,059,000

Reuters
·
Aug 01

Alnylam Lowers 2026 Outlook As Second-Line Amvuttra Demand Normalizes, Stock Tanks

Benzinga Earnings
·
Jul 31

Ionis Pharmaceuticals: Strong Commercial Momentum and Late‑Stage Pipeline Catalysts Drive Buy Rating

TIPRANKS
·
Jul 31

Ionis Pharmaceuticals is Maintained at Overweight by Wells Fargo

Dow Jones
·
Jul 30

Alnylam Q2 Revenue Rises 67% on Increased Demand for Amvuttra

Reuters
·
Jul 30

RBC Capital Reaffirms Their Buy Rating on Ionis Pharmaceuticals (IONS)

TIPRANKS
·
Jul 30

Ionis Pharmaceuticals price target lowered to $115 from $125 at H.C. Wainwright

TIPRANKS
·
Jul 30